Serial comprehensive geriatric and quality of life assessments in adults age ≥ 50 years undergoing autologous hematopoietic cell transplantation
Mariam T Nawas,Ying Sheng,Chiung-Yu Huang,Charalambos Andreadis,Thomas G Martin,Jeffrey L Wolf,Weiyun Z Ai,Lawrence D Kaplan,Gabriel N Mannis,Aaron C Logan,Lloyd E Damon,Rebecca L Olin,Mariam T. Nawas,Thomas G. Martin,Jeffrey L. Wolf,Weiyun Z. Ai,Lawrence D. Kaplan,Gabriel N. Mannis,Aaron C. Logan,Lloyd E. Damon,Rebecca L. Olin
DOI: https://doi.org/10.1016/j.jgo.2020.09.027
IF: 3.929
2021-05-01
Journal of Geriatric Oncology
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Objectives</h3><p>We sought to examine the natural history of geriatric assessment (GA) and quality of life (QOL) domains among adults age ≥ 50 years undergoing autologous hematopoietic cell transplantation (autoHCT).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Materials and Methods</h3><p>A QOL tool and cancer-specific GA were completed before autoHCT in patients ≥50 years, and at 100 days, six months, and one year post-transplant.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>One hundred eighty-four patients completed the pre-transplant QOL/GA assessment, 169 (92%) completed the 100-day assessment, 162 (88%) completed the six-month assessment, and 145 (79%) completed the twelve-month assessment. Functional status, as measured by instrumental activities of daily living (IADL), decreased from baseline to day 101 (mean change −0.42 points, 95% CI, −0.75 to −0.09, <em>p</em> = 0.01) but returned to baseline by one year. Physical function as measured by Medical Outcomes Study-Physical Health (MOS-PH) increased by mean of 3.27 points (95% CI, −0.02 to 6.56, <em>p</em> = 0.05) by one year. Physician-rated KPS improved by one year, but patient-rated KPS did not. No QOL metric deteriorated from baseline. Baseline factors predictive of IADL and MOS-PH as measured over time included comorbidities and disease status at transplant. IADL and MOS-PH as measured over time were not significantly associated with age.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>AutoHCT for adults age ≥ 50 years resulted in an initial decrease in functional status, with subsequent improvement back to baseline by one year. Physical health and QOL measures were improved or unchanged over time. AutoHCT is well tolerated in well selected older patients, using patient reported geriatric metrics as outcomes.</p>
oncology,geriatrics & gerontology,gerontology